

Approved Biotechnology Products

Product Name	Company	Product Category	Indication
Actimmune® interferon gamma-1b	InterMune <i>Brisbane, CA</i>	interferon	management of chronic granulomatous disease (December 1990); malignant osteopetrosis (February 2000)
Activase® alteplase, recombinant	Genentech <i>South San Francisco, CA</i>	tissue plasminogen activator	acute myocardial infarction (November 1987); acute massive pulmonary embolism (June 1990); acute myocardial infarction (accelerated infusion) (April 1995); ischemic stroke within 3 to 5 hours of symptom onset (June 1996)
Adagen® Injection pegademase bovine	Enzon <i>Bridgewater, NJ</i>	enzyme replacement therapy	treatment of severe combined immunodeficiency disease (SCID) (March 1990)
Advate antihemophilic factor (recombinant) plasma/albumin-free method	Baxter Healthcare <i>Deerfield, IL</i>	recombinant factor VIII	hemophilia A (July 2003)
Aldurazyme® laronidase for injection (Orphan Drug)	BioMarin Pharmaceutical <i>Novato, CA</i> Genzyme <i>Cambridge, MA</i>	enzyme replacement therapy	treatment of mucopolysaccharidosis-I (MPS-I) (April 2003)
Alferon N Injection® Interferon alfa-n2	Hemispherx Biopharma <i>New Brunswick, NJ</i> <i>Philadelphia, PA</i>	interferon	genital warts (October 1989)
Amevive® alefacept	Biogen Idec <i>Cambridge, MA</i>	fusion protein	moderate to severe chronic plaque psoriasis (January 2003)
Apidra® insulin glulisine (rDNA origin) injection	sanofi-aventis <i>Bridgewater, NJ</i>	recombinant insulin	treatment of adults with diabetes mellitus for the control of hyperglycemia (April 2004)
Apligraf™ graftskin	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	cell/tissue therapy	treatment of venous leg ulcers (May 1998)
Aranesp® darbepoetin alfa	Amgen <i>Thousand Oaks, CA</i>	recombinant protein	treatment of anemia in chronic renal failure (September 2001); treatment of chemotherapy-induced anemia (July 2002)
Avastin™ bevacizumab	Genentech <i>South San Francisco, CA</i>	MAb	in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with first-line—or previously untreated—metastatic colorectal cancer (February 2004)
Avonex® interferon beta-1a	Biogen Idec <i>Cambridge, MA</i>	interferon	relapsing multiple sclerosis (May 1996); treatment after initial multiple sclerosis attack if a brain MRI shows abnormalities characteristic of the disease (February 2003)
BeneFIX™ coagulation factor IX	Wyeth <i>Collegeville, PA</i>	clotting factor	hemophilia B (February 1997)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Betaseron [®] recombinant interferon beta-1b	Berlex Laboratories <i>Montville, NJ</i> Chiron <i>Emeryville, CA</i>	interferon	relapsing-remitting multiple sclerosis (July 1993); relapsing forms of multiple sclerosis (March 2003)
Bexxar [®] tositumomab, iodine I 131 tositumomab	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	radio- immunotherapy MAb	CD20-positive, follicular non-Hodgkin's lymphoma (June 2003); CD20 antigen-expressing relapsed or refractory, low-grade, follicular or transformed non-Hodgkin's lymphoma (January 2005)
BioTropin [™] human growth hormone	Bio-Technology General <i>Iselin, NJ</i>	human growth hormone	growth hormone deficiency in children (May 1995)
Campath [®] alemtuzumab	Berlex Laboratories <i>Montville, NJ</i> Genzyme <i>Cambridge, MA</i>	MAb	treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy (May 2001); single-use vial (October 2004)
Carticel [®] autologous cultured chondrocytes	Genzyme <i>Cambridge, MA</i>	autologous cell therapy	repair of symptomatic cartilaginous defects of the femoral condyle (medial, lateral, or trochlear) caused by acute or repetitive trauma (August 1997)
CEA-Scan [®] technetium-99m- arctumomab	Immunomedics <i>Morris Plains, NJ</i>	monoclonal antibody (MAb), Fab' fragment	presence, location and detection of recurrent and metastatic colorectal cancer (June 1996)
Cerezyme [®] imiglucerase for injection	Genzyme <i>Cambridge, MA</i>	enzyme replacement therapy	treatment of type 1 Gaucher disease (May 1994)
Comvax [™] Haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b recombinant vaccine	Merck <i>Whitehouse Station, NJ</i>	recombinant vaccine	vaccination of infants beginning at two months of age against both invasive <i>Haemophilus influenzae</i> type b diseases (Hib) and hepatitis B (October 1996)
DACS [™] SC stem cell enrichment device	Dendreon <i>Seattle, WA</i>	cell/tissue therapy	rescue therapy following high-dose chemotherapy (August 1999)
Elitek [®] rasburicase	sanofi-aventis <i>Bridgewater, NJ</i>	recombinant enzyme	prophylaxis for chemotherapy-related hyperuricemia, treatment of cancer-related hyperuricemia (July 2002)
Enbrel [®] etanercept	Amgen <i>Thousand Oaks, CA</i> Wyeth <i>Collegeville, PA</i>	recombinant soluble receptor	moderate to severe active rheumatoid arthritis (November 1998); moderate to severe active juvenile rheumatoid arthritis (May 1999); psoriatic arthritis (January 2002); disease modification of active rheumatoid arthritis, ankylosing spondylitis (July 2003); psoriasis (April 2004); psoriatic arthritis (June 2005)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Engerix-B® hepatitis B vaccine (recombinant)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	recombinant vaccine	hepatitis B (September 1989); adult chronic hepatitis C (August 1998)
EPOGEN® Epoetin alfa (rEPO)	Amgen <i>Thousand Oaks, CA</i>	erythropoietin	treatment of anemia associated with chronic renal failure, including patients on dialysis and not on dialysis, and anemia in Retrovir®-treated HIV-infected patients (June 1989); treatment of anemia caused by chemotherapy in patients with non-myeloid malignancies (April 1993); prevention of anemia associated with surgical blood loss, autologous blood donation adjuvant (December 1996); anemia in children with chronic renal failure who are currently undergoing dialysis (November 1999)
Erbix™ cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> Medarex <i>Princeton, NJ</i>	MAB	colorectal cancer (February 2004); squamous cell cancer of the head and neck (March 2006)
Exubera® insulin human (rDNA origin) inhalation powder	Nektar Therapeutics <i>San Carlos, CA</i> Pfizer <i>New York, NY</i>	recombinant insulin	treatment of adults with type 1 and type 2 diabetes (January 2006)
Fabrazyme® agalsidase beta (Orphan Drug)	Genzyme <i>Cambridge, MA</i>	enzyme replacement therapy	treatment of Fabry disease (April 2003)
Follistim® recombinant follicle-stimulating hormone	Organon <i>West Orange, NJ</i>	recombinant hormone	infertility (September 1997); induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism (February 2002)
Fortéo® teriparatide injection rDNA origin	Eli Lilly <i>Indianapolis, IN</i>	recombinant DNA origin	osteoporosis (November 2002)
Fortical® Nasal Spray calcitonin salmon	Unigene Laboratories <i>Fairfield, NJ</i>	recombinant peptide	postmenopausal osteoporosis in women with low bone mass (August 2005)
Genotropin® somatotropin (rDNA origin) for injection	Pfizer <i>New York, NY</i>	human growth hormone	short stature in children due to growth hormone deficiency (August 1995); adult growth hormone deficiency (November 1997); growth failure due to Prader-Willi syndrome (June 2000); long-term treatment of growth failure in children born small for gestational age (July 2001)
Geret® human growth hormone-releasing factor (Orphan Drug)	Serono <i>Rockland, MA</i>	growth factor	evaluation of the ability of the somatotroph of the pituitary gland to secrete growth hormone (December 1990); pediatric growth hormone deficiency (October 1997)
GlucaGen® glucagon (rDNA origin) for injection	Novo Nordisk <i>Princeton, NJ</i>	recombinant human protein	treatment of hypoglycemia and for use as a diagnostic aid (June 1998)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Gonal-F® recombinant human follicle-stimulating hormone (r-FSH)	Serono <i>Rockland, MA</i>	recombinant fertility hormone	female infertility (September 1997); induction of spermatogenesis in men with hypogonadotropic hypogonadism (June 2000)
Helixate® FS antihemophilic factor (recombinant)	Aventis Behring <i>King of Prussia, PA</i>	clotting factor	treatment of hemophilia A (June 2000)
Herceptin® trastuzumab	Genentech <i>South San Francisco, CA</i>	MAb	treatment of HER2-overexpressing metastatic breast cancer (September 1998)
Humalog® insulin lispro recombinant	Eli Lilly <i>Indianapolis, IN</i>	recombinant insulin	diabetes (June 1996)
Humatrope® somatropin (rDNA origin) for injection	Eli Lilly <i>Indianapolis, IN</i>	human growth hormone	treatment of short stature associated with Turner's syndrome (December 1996); human growth hormone deficiency in children (March 1987); long-term treatment of children with short stature (July 2003)
Humira® adalimumab	Abbott Laboratories <i>Abbott Park, IL</i>	MAb	rheumatoid arthritis (December 2002)
Humulin® human insulin (recombinant DNA origin)	Eli Lilly <i>Indianapolis, IN</i>	recombinant insulin	diabetes (October 1982)
Hylenex™ recombinant human hyaluronidase injection	Baxter Healthcare <i>Deerfield, IL</i> Halozyme <i>San Diego, CA</i>	recombinant enzyme	adjuvant to increase absorption and dispersion of other injected drugs; hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents (December 2005)
Increlex™ mecasermin (rDNA origin) injection	Tercica <i>Brisbane, CA</i>	recombinant hormone	long-term treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion (August 2005)
Infergen® interferon alfacon-1	Amgen <i>Thousand Oaks, CA</i>	interferon	treatment of chronic hepatitis C viral infection (October 1997)
Infuse® Bone Graft device utilizing recombinant human bone morphogenetic protein (rhBMP-2)	MedTronic <i>Minneapolis, MN</i> Wyeth <i>Collegeville, PA</i>	recombinant growth factor	for use in spinal fusion surgery to treat certain types of spinal degenerative disease (July 2002); acute open tibia shaft fractures in adults (April 2004)
Intron® A interferon alfa-2b (recombinant)	Schering-Plough <i>Kenilworth, NJ</i>	interferon	hairy cell leukemia (June 1986); genital warts (June 1988); AIDS-related Kaposi's sarcoma (November 1988); hepatitis C (February 1991); hepatitis B (July 1992); malignant melanoma (December 1995); follicular lymphoma in conjunction with chemotherapy (November 1997); treatment of hepatitis B in pediatric patients (August 1998)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
iPlex™ mecasermin rinfabate (rDNA origin) injection	Insmed <i>Richmond, VA</i>	recombinant hormone	long-term treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion (December 2005)
Kepivance™ palifemin	Amgen <i>Thousand Oaks, CA</i>	recombinant growth factor	treatment of severe oral mucositis (mouth sores) in patients undergoing chemotherapy (December 2004)
Kineret® anakinra	Amgen <i>Thousand Oaks, CA</i>	recombinant protein	signs and symptoms of rheumatoid arthritis (November 2001)
KoGENate® antihemophiliac factor (recombinant)	Bayer <i>West Haven, CT</i>	clotting factor	treatment of hemophilia A (February 1993)
KoGENate-FS rFVIII	Bayer <i>West Haven, CT</i>	clotting factor	hemophilia A (June 2000)
Lantus® insulin glargine (rDNA origin) injection	sanofi-aventis <i>Bridgewater, NJ</i>	recombinant insulin	adults with type 2 diabetes or adults and children (6 years and older) with type 2 diabetes who require long-acting insulin for the control of high blood sugar (April 2000)
Leukine™ sargramostim (GM-CSF)	Berlex Laboratories <i>Montville, NJ</i>	colony stimulating factor	autologous bone marrow transplantation (March 1991); neutropenia resulting from chemotherapy in acute myelogenous leukemia (September 1995); allogeneic bone marrow transplantation (November 1995); peripheral blood progenitor cell mobilization and transplantation (December 1995)
Levemir® insulin detemir	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus (June 2005)
Luveris® lutropin alfa for injection (Orphan Drug)	Serono <i>Rockland, MA</i>	recombinant protein	follicular development in infertile hypogonadotropic hypogonadal women with profound luteinizing hormone deficiency (October 2004)
LYMErix™ Lyme disease vaccine (recombinant OspA)	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	vaccine	prevention of Lyme disease (December 1998)
Macugen® pegaptanib sodium injection	Pfizer <i>New York, NY</i>	vascular endothelial growth factor	treatment of neovascular (wet) age-related macular degeneration (December 2004)
Mylotarg™ gemtuzumab ozogamicin	Wyeth <i>Collegeville, PA</i>	MAb	treatment of patients 60 years and older in first relapse with CD33-positive acute myeloid leukemia (AML) who are not considered candidates for cytotoxic chemotherapy (May 2000)
Naglazyme™ galsulfase	BioMarin Pharmaceutical <i>Novato, CA</i>	enzyme replacement therapy	treatment of MPS VI (mucopolysaccharidoses VI) (May 2005)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Natrecor [®] nesiritide	Scios <i>Sunnyvale, CA</i>	recombinant human peptide	acute decompensated congestive heart failure (August 2001)
Neulasta [®] pegfilgrastim	Amgen <i>Thousand Oaks, CA</i>	colony stimulating factor	chemotherapy-induced neutropenia (January 2002)
Neumega [®] oprelvekin	Wyeth <i>Collegeville, PA</i>	interleukin	prevention of severe thrombocytopenia, reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adults (November 1997)
NEUPOGEN [®] filgrastim (rG-CSF)	Amgen <i>Thousand Oaks, CA</i>	colony stimulating factor	chemotherapy-induced neutropenia (February 1991); autologous or allogeneic bone marrow transplantation (June 1994); chronic severe neutropenia (December 1994); support peripheral blood progenitor cell transplantation (December 1995); acute myelogenous leukemia (April 1998)
NeuroSpec [™] technetium 99m Tc fanolesomab	Palatin Technologies <i>Cranbury, NJ</i>	MAB	diagnosis of appendicitis in patients with equivocal signs (July 2004)
Norditropin [®] somatropin (rDNA origin) for injection	Novo Nordisk <i>Princeton, NJ</i>	recombinant human growth hormone	treatment of growth failure in children due to inadequate growth hormone secretion (May 1995); replacement of endogenous growth hormone in adults with adult or childhood onset of growth hormone deficiency (November 2004)
Novolin [®]	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus for the control of hyperglycemia (October 1982)
Novolin [®] 70/30 70% NPH human insulin isophane suspension & 30% regular, human insulin injection (recombinant DNA origin)	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus for the control of hyperglycemia (June 1991)
Novolin [®] L Lente [®] , human insulin zinc suspension (recombinant DNA origin)	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus for the control of hyperglycemia (June 1991)
Novolin [®] N NPH, human insulin isophane suspension (recombinant DNA origin)	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus for the control of hyperglycemia (June 1991)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Novolin® R regular, human insulin injection (recombinant DNA origin)	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus for the control of hyperglycemia (June 1991)
NovoLog® insulin aspart (rDNA origin) injection	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus (May 2000)
NovoLog® Mix 70/30 70% insulin aspart (rDNA origin) protamine suspension and 30% insulin aspart (rDNA origin) injection	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus (November 2001)
NovoSeven® coagulation factor VIIa (recombinant)	Novo Nordisk <i>Princeton, NJ</i>	recombinant human protein	treatment of bleeding episodes in hemophilia A or B patients with inhibitors to factor VIII or factor IX (March 1999); treatment of bleeding episodes in patients with congenital factor VII deficiency (July 2005); prevention of bleeding in surgical interventions or invasive procedures in patients with congenital factor VII deficiency (July 2005); prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to factor VIII or factor IX (August 2005)
Nutropin® somatotropin (rDNA origin) for injection	Genentech <i>South San Francisco, CA</i>	recombinant human growth hormone	growth failure in children due to chronic renal insufficiency, growth hormone inadequacy in children (March 1994); Turner's syndrome (December 1996); growth hormone inadequacy in adults (December 1997); idiopathic short stature (July 2005)
Nutropin AQ™ somatotropin (rDNA origin) (liquid)	Genentech <i>South San Francisco, CA</i>	recombinant human growth hormone	growth failure in children due to chronic renal insufficiency, growth hormone inadequacy in children (December 1995); Turner's syndrome (December 1996); growth hormone inadequacy in adults (December 1997); idiopathic short stature (July 2005)
OncoScint® CR/OV satumomab pendetide	CYTOGEN <i>Princeton, NJ</i>	MAB	detection, staging and follow-up of colorectal and ovarian cancers (December 1992)
Oncospar® PEG-L-asparaginase	Enzon <i>Bridgewater, NJ</i>	pegylated-enzyme	first-line treatment of acute lymphoblastic leukemia (February 1994)
Ontak® denileukin diftitox	Ligand Pharmaceuticals <i>San Diego, CA</i>	fusion protein	persistant or recurrent cutaneous T-cell lymphoma (February 1999)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Orencia™ abatacept	Bristol-Myers Squibb <i>Princeton, NJ</i>	recombinant soluble receptor	rheumatoid arthritis (December 2005)
ORTHOCLONE OKT®3 muromonab-CD3	Ortho Biotech <i>Raritan, NJ</i>	MAB	reversal of acute kidney transplant rejection (June 1991); reversal of heart and liver transplant rejection (June 1993)
Ovidrel® choriogonadotropin alfa injection	Serono <i>Rockland, MA</i>	recombinant protein	induction of final follicular maturation and early luteinization (October 2003)
Pediarix™ diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	recombinant antigen	immunization of infants at 2, 4 and 6 months of age against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and polio (December 2002)
Pegasys® peginterferon alfa-2a	Roche <i>Nutley, NJ</i>	interferon	chronic hepatitis C (December 2002); chronic hepatitis B (May 2005)
Pegasys® pegylated interferon alfa-2a and ribivirin combination	Roche <i>Nutley, NJ</i>	interferon	chronic hepatitis C (December 2002)
PEG-Intron® peginterferon alfa-2b	Schering-Plough <i>Kenilworth, NJ</i>	interferon	hepatitis C (August 2001)
Prevnar® pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein)	Wyeth <i>Collegeville, PA</i>	recombinant vaccine	active immunization of infants and toddlers against invasive disease caused by <i>S. pneumoniae</i> due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 19F and 23F) (February 2000)
PROCRIT® epoetin alfa (rEPO)	Ortho Biotech <i>Raritan, NJ</i>	erythropoietin	treatment of anemia associated with chronic renal failure, including patients on dialysis and not on dialysis, and anemia in Retrovir®-treated HIV-infected patients (December 1990); treatment of anemia caused by chemotherapy in patients with non-myeloid malignancies (April 1993); prevention of anemia associated with surgical blood loss, autologous blood donation adjuvant (December 1996); anemia in children with chronic renal failure who are currently undergoing dialysis (July 1999)
<p><i>[PROCRIT® was approved for marketing under Amgen's epoetin alfa PLA. Amgen manufactures the product for Ortho Biotech.] Under an agreement between the two companies, Amgen licensed to Ortho Pharmaceutical the U.S. rights to epoetin alfa for indications for human use excluding dialysis and diagnostics.</i></p>			
Proleukin® aldesleukin (interleukin-2)	Chiron <i>Emeryville, CA</i>	interleukin	renal cell carcinoma (May 1992); metastatic melanoma (January 1998)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
ProstaScint® capromab pentetate	CYTOGEN <i>Princeton, NJ</i>	MAB	detection, staging and follow-up of prostate adenocarcinoma (October 1996)
Protropin® somatrem for injection	Genentech <i>South San Francisco, CA</i>	human growth hormone	human growth hormone deficiency in children (October 1985)
Pulmozyme® dornase alpha, recombinant	Genentech <i>South San Francisco, CA</i>	recombinant DNase	cystic fibrosis (December 1993); management of advanced cystic fibrosis (December 1996)
Raptiva® efalizumab	Genentech <i>South San Francisco, CA</i> XOMA <i>Berkeley, CA</i>	MAB	chronic moderate to severe plaque psoriasis (October 2003)
Rebetron™ ribavirin/interferon alfa-2b, combination therapy	Schering-Plough <i>Kenilworth, NJ</i>	interferon	treatment of chronic hepatitis C in patients who have relapsed following alpha interferon therapy (June 1998); treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with alpha interferon therapy (December 1999)
Rebif® interferon beta-1a	Serono <i>Rockland, MA</i>	interferon	relapsing forms of multiple sclerosis (March 2002)
recombinant human bone morphogenetic protein-2/ Absorbable Collagen Sponge (rhBMP-2/ACS)	Wyeth <i>Philadelphia, PA</i>	growth factor	bone and tissue repair
Recombinate™ antihemophilic factor recombinant (rAHF)	Baxter Healthcare <i>Deerfield, IL</i> Wyeth <i>Philadelphia, PA</i>	clotting factor	prevention and control of bleeding episodes in patients with hemophilia A (December 1992)
RECOMBIVAX HB® hepatitis B vaccine (recombinant)	Merck <i>Whitehouse Station, NJ</i>	recombinant vaccine	hepatitis B prevention (July 1986)
ReFacto® antihemophilic factor, recombinant (factor VIII)	Wyeth <i>Collegeville, PA</i>	clotting factor	hemophilia A (March 2000)
Refludan™ lepirudin [rDNA] for injection	Berlex Laboratories <i>Montville, NJ</i>	recombinant anticoagulant	heparin-induced thrombocytopenia type II (March 1998)
Regranex® becaplermin (recombinant human platelet- derived growth factor-BB)	Ortho-McNeil Pharmaceuticals <i>Raritan, NJ</i>	growth factor	chronic diabetic ulcers (December 1997)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Remicade™ infliximab	Centocor <i>Malvern, PA</i>	MAB	short-term use in Crohn's disease (August 1998); reduction of signs and symptoms in rheumatoid arthritis (November 1999); inhibit the progression of structural damage in patients with rheumatoid arthritis (January 2001); improve physical function in patients with rheumatoid arthritis (February 2002); long-term remission-level control of Crohn's disease (July 2002)
ReoPro® abciximab	Centocor <i>Malvern, PA</i> Eli Lilly <i>Indianapolis, IN</i>	MAB	anti-platelet prevention of blood clots in the setting of high-risk percutaneous transluminal coronary angioplasty (December 1994); refractory unstable angina when percutaneous coronary intervention is planned (November 1997)
Retavase® reteplase	Centocor <i>Malvern, PA</i>	tissue plasminogen factor	treatment of acute myocardial infarction (October 1996)
Rituxan® ritiximab	Genentech <i>South San Francisco, CA</i> Biogen Idec <i>Cambridge, MA</i>	MAB	treatment of relapsed or refractory low-grade or follicular CD20-positive B-cell non-Hodgkin's lymphoma (November 1997); retreatment of patients who have relapsed following initial Rituxan treatment, eight week doses (compared to original four), and treatment of bulky disease (April 2001); first-line treatment of diffuse large B0-cell, CD20-positive, non-Hodgkin's lymphoma in combination with other chemotherapy regimens (February 2006); reduction of signs and symptoms of adult moderate to severe active rheumatoid arthritis in combination with methotrexate (February 2006)
Roferon®-A interferon alfa-2a, recombinant	Roche <i>Nutley, NJ</i>	interferon	hairy cell leukemia (June 1986); AIDS-related Kaposi's sarcoma (November 1988); chronic myelogenous leukemia (November 1995); hepatitis C (November 1996)
Saizen® somatropin (rDNA origin) for injection	Serono <i>Rockland, MA</i>	human growth hormone	pediatric growth hormone deficiency (October 1996)
Serostim™ somatropin (rDNA origin) for injection (Orphan Drug)	Serono <i>Rockland, MA</i>	human growth hormone	treatment of AIDS-associated catabolism/wasting (August 1996); pediatric HIV failure to thrive (February 1998)
Simulect® basiliximab	Novartis Pharmaceuticals <i>East Hanover, NJ</i>	MAB	prevention of renal transplant rejection (May 1998)
Somavert® pegvisomant for injection	Pfizer <i>New York, NY</i>	growth hormone receptor antagonist	treatment of acromegaly (March 2003)
Synagis® palivizumab	MedImmune <i>Gaithersburg, MD</i>	MAB	prevention of respiratory syncytial virus (RSV) (June 1998)

APPROVED BIOTECHNOLOGY PRODUCTS

Product Name	Company	Product Category	Indication
Thymoglobulin® thymocyte globulin (rabbit)	Genzyme <i>Cambridge, MA</i>	polyclonal antibody	prevention of kidney transplant rejection (December 1998)
Thyrogen® thyrotropin alfa for injection	Genzyme <i>Cambridge, MA</i>	recombinant hormone (diagnostic)	thyroid cancer follow-up (November 1998)
TNKase™ tenecteplase	Genentech <i>South San Francisco, CA</i>	thrombolytic	acute myocardial infarction (June 2000)
Twinrix® hepatitis A inactivated and hepatitis B (recombinant) vaccine	GlaxoSmithKline <i>Philadelphia, PA</i> <i>Rsch. Triangle Park, NC</i>	recombinant antigen	immunization against hepatitis A and B viruses (May 2001)
Tysarbi® natalizumab	Biogen Idec <i>Cambridge, MA</i>	MAb	treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses (November 2004)
Velosulin® BR buffered regular human insulin injection (rDNA origin)	Novo Nordisk <i>Princeton, NJ</i>	recombinant insulin	treatment of diabetes mellitus for the control of hyperglycemia (July 1999)
Verluma® nofetumomab	DuPont Pharmaceuticals <i>Billerica, MA</i>	MAb	detection of small-cell lung cancer (August 1996)
Visudyne® verteporfin	QLT <i>Vancouver, British Columbia</i>	photodynamic therapy	age-related macular degeneration, ocular histoplasmosis, pathologic myopia (April 2000)
Vitravene® fomiviren sodium injectable	Ciba Vision <i>Duluth, GA</i> Isis Pharmaceuticals <i>Carlsbad, CA</i>	antisense	treatment of cytomegalovirus retinitis in patients with AIDS (August 1998)
Xigris™ drotrecogin alfa (activated)	Eli Lilly <i>Indianapolis, IN</i>	recombinant activated protein C	severe sepsis (November 2001)
Xolair® omalizumab	Genentech <i>South San Francisco, CA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i> Tanox <i>Houston, TX</i>	MAb	treatment of moderate to severe allergy-related asthma (12 years and older) (June 2003)
Zenapax® daclizumab	Roche <i>Nutley, NJ</i> Protein Design Labs <i>Fremont, CA</i>	MAb	prophylaxis of acute kidney transplant rejection (December 1997)
Zevalin™ ibritumomab tiuxetan	IDEC Pharmaceuticals <i>San Diego, CA</i>	MAb	treatment of relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (February 2002)
Zorbitive™ somatropin [rDNA origin] for injection	Serono <i>Rockland, MA</i>	recombinant protein	for patients with short bowel syndrome requiring specialized nutritional support (December 2003)